Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CET
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at kristin.jones@dowjones.com

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
03/16 IMMUNOMEDICS,INC. (NASDAQ : IMMU) Files An 8-K Submission of Matters to a Vote o..
03/16 IMMUNOMEDICS INC : Submission of Matters to a Vote of Security Holders (form 8-K..
03/16 IMMUNOMEDICS : Submission of Matters to a Vote of Security Holders (form 8-K/A)
03/15 IMMUNOMEDICS : Announces publication of results in journal of clinical oncology,..
03/10 IMMUNOMEDICS, INC. : Markets Rally Late to Close in the Green: Today's Research ..
03/10 HERE’S WHAT’S MOVING IMM : IMMU) and Ocera Therapeutics Inc (NASDAQ:..
03/10 SEATTLE GENETICS' : big deal held up as partner's shareholders do battle
03/09 IMMUNOMEDICS,INC. (NASDAQ : IMMU) Files An 8-K Submission of Matters to a Vote o..
03/09 IMMUNOMEDICS INC : Submission of Matters to a Vote of Security Holders (form 8-K..
03/03 IMMUNOMEDICS : Stockholders Endorse venBio’s Case for Meaningful Change at..
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/14 WHY SHOULD INVESTORS CONSIDER AN ALL : A Sector Analysis
03/10 Activist Investor Puts Immunomedics Phase III In Play
03/09 Jefferies analyst says Immunomedics' IMMU-132 deal with Seattle Genetics not ..
03/09 Immunomedics' IMMU-132 deal on hold; shares rally 11%; Seattle Genetics down ..
03/08 3 Early- To Mid-Stage Growing Speculative Immuno-Oncology Companies With Posi..
Advertisement
Financials ($)
Sales 2017 15,1 M
EBIT 2017 -48,0 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 45,3x
Capi. / Sales 2018 10,3x
Capitalization 681 M
More Financials
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 7,50 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Cynthia L. Sullivan President, Chief Executive Officer & Director
David M. Goldenberg Chairman, Chief Scientific & Patent Officer
Michael R. Garone Chief Financial Officer & Vice President-Finance
William A. Wegener Chief Medical Officer
Brian A. Markison Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.74.93%681
INCYTE CORPORATION40.90%28 796
QUINTILES IMS HOLDINGS..1.95%18 291
LONZA GROUP AG4.76%10 574
CELLTRION, INC.--.--%9 774
ALKERMES PLC6.93%9 066
More Results